Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPN424 in advanced prostate cancer
NCT03577028Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Modality
- T-cell Engagers, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of HPN424 in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Merck & Co. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Jul 2018; status: terminated.
02
Drugs
HPN424
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03577028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577028.